ZNF521 which is downregulated by miR-802 suppresses malignant progression of Hepatocellular Carcinoma through regulating Runx2 expression

Yang, Nan; Wang, Liang; Chen, Tianxiang; Liu, Runkun; Liu, Zhikui; Zhang, Lei

doi:10.7150/jca.45190

Cited by 20 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro experiments also further showed that miR-802 promoted the proliferation of lung cancer cells. 35 The abnormal expression of miR-802 has been confirmed in the tumor tissues or tumor cells of 15 cancers, including TSCC, 4 OSCC, 5,6 LSCC, 8 GC, [9][10][11] CRC, [12][13][14] PC, [30][31][32] HCC, [22][23][24][25] PCa, 2,33 bladder urothelial cancer, 26 BC, 15,16 CC, [17][18][19] EOC, 20 lung cancer, [34][35][36] osteosarcoma, 27,28 and melanoma. 21 To note, the abnormal expression of miR-802 in ESCC 7 and cholesteatoma 29 has only been confirmed in tumor cells.…”

Section: Ab Err Ant E Xpre Ss I On Of Mir-8 0in Tumor Smentioning

confidence: 99%

Dysfunction of miR‐802 in tumors

Gao

Zou

Duan

2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of small ribonucleic acids (19-24 nucleotides). 1 miRNAs play an important role in post-transcriptional gene silencing (PTGS). 1 Thousands of miRNAs have been discovered, and they can regulate more than 30% of gene expression. 2 The miR-NAs can be detected in about 50% of the mutated regions in tumor tissues, suggesting that miRNAs may be closely related to the occurrence and development of tumors. 2MicroRNA-802 (miR-802) gene is located on chromosome 21, and its precursor can be processed into two functional mature miRNAs (miR-802-3p and miR-802-5p). Among them, miR-802-3p is much richer than miR-802-5p. 3 Current studies have found that miR-802 is abnormally expressed in a variety of tumor tissues and cells, suggesting that the expression of miR-802 may be related to tumors. This review reports the abnormal expression of miR-802 in various tumors including tongue squamous cell carcinoma (TSCC), oral squamous cell carcinoma (OSCC), esophageal squamous cell

show abstract

Section: Ab Err Ant E Xpre Ss I On Of Mir-8 0in Tumor Smentioning

confidence: 99%

Dysfunction of miR‐802 in tumors

Gao

Zou

Duan

2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Compared to pancreatic cancers, hepatocellular carcinomas (HCC) express high miR-802, which is up-regulated compared to adjacent, non-tumor tissues. In 2020, Yang et al [35] demonstrated that ZNF521 expression was abnormally down-regulated by miR-802 both in HCC tissues and liver cancer cell lines resulting in a malignant progression of the tumor. It was demonstrated by transcription reporter assays that miR-802 was physically involved in regulating ZNF521 expression binding to the miR-802 site in the 3 UTR of ZNF521 in HCCs.…”

Section: Interplay Between Mirnas and Znf521 In Pancreatic And Liver Cancermentioning

confidence: 99%

“…In addition, it was shown in HCC cells that ZNF521, acting as a co-transcriptional repressor, binding Runx2 [36] and inhibiting its transcriptional activity involving PI3K/AKT signaling, blocks the tumor progression [35]. Runx2 is a bone-specific transcriptional regulator required during embryogenesis for skeletal development and is the main marker of osteoblastic differentiation [37,38]; the mouse protein, Zfp521, is able to bind Runx2 and antagonize its transcriptional activity, thereby controlling osteoblast differentiation from mesenchymal stem cells in vitro [39].…”

Section: Interplay Between Mirnas and Znf521 In Pancreatic And Liver Cancermentioning

confidence: 99%

“…Down-regulated ZNF521 expression may be relevant as a prognostic factor in malignant HCC, especially in the tumor TNM stage that is associated with poor prognosis. Understanding of the molecular relationship between miR-802 and ZNF521 could represent an advanced approach for in vitro diagnostics as well as a potential targeting strategy for treatment of HCC [35,43] (Figure 3). in many cancer cells promoting tumor progression [40].…”

Section: Interplay Between Mirnas and Znf521 In Pancreatic And Liver Cancermentioning

confidence: 99%

“…Down-regulated ZNF521 expression may be relevant as a prognostic factor in malignant HCC, especially in the tumor TNM stage that is associated with poor prognosis. Understanding of the molecular relationship between miR-802 and ZNF521 could represent an advanced approach for in vitro diagnostics as well as a potential targeting strategy for treatment of HCC [35,43] (Figure 3). In 2014, Bai and colleagues performed an integrated analysis of miRNA and mRNA in HCC cells; they compared miRNA and mRNA expression profiling in HepG2 cells and normal liver HL-7702 cells using next-generation sequencing technology.…”

Section: Interplay Between Mirnas and Znf521 In Pancreatic And Liver Cancermentioning

confidence: 99%

See 2 more Smart Citations

Regulatory Role of microRNAs Targeting the Transcription Co-Factor ZNF521 in Normal Tissues and Cancers

Chiarella

Aloisio

Scicchitano

et al. 2021

IJMS

View full text Add to dashboard Cite

Powerful bioinformatics tools have provided a wealth of novel miRNA–transcription factor networks crucial in controlling gene regulation. In this review, we focus on the biological functions of miRNAs targeting ZNF521, explaining the molecular mechanisms by which the dysregulation of this axis contributes to malignancy. ZNF521 is a stem cell-associated co-transcription factor implicated in the regulation of hematopoietic, neural, and mesenchymal stem cells. The aberrant expression of ZNF521 transcripts, frequently associated with miRNA deregulation, has been detected in several tumors including pancreatic, hepatocellular, gastric, bladder transitional cell carcinomas as well as in breast and ovarian cancers. miRNA expression profiling tools are currently identifying a multitude of miRNAs, involved together with oncogenes and TFs in the regulation of oncogenesis, including ZNF521, which may be candidates for diagnostic and prognostic biomarkers of cancer.

show abstract

Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review

Ravegnini

Gorini

Crescenzo

et al. 2021

Intl Journal of Cancer

View full text Add to dashboard Cite

Endometrial cancer (EC) is the most common gynecological cancer, with annual incidence rates in Western countries ranging between 15 and 25 per 100 000 women. About 15% to 20% of patients with EC have high‐risk disease and follow an aggressive clinical course. Unfortunately, the assessment of histologic parameters is poorly reproducible and conventional clinicopathological and molecular features do not reliably predict either the patient's response to the available treatments or the definition of personalized therapeutic approaches. In this context, the identification of novel diagnostic and prognostic biomarkers, which can be integrated in the current classification schemes, represents an unmet clinical need and an important challenge. miRNAs are key players in cancer by regulating the expression of specific target genes. Their role in EC, in association with clinical and prognostic tumor biomarkers, has been investigated but, so far, with little consensus among the studies. The present review aims to describe the recent advances in miRNAs research in EC taking into consideration the current classification schemes and to highlight the most promising miRNAs. Finally, a perspective point of view sheds light on the challenges ahead in the landscape of EC.

show abstract

ZNF521 which is downregulated by miR-802 suppresses malignant progression of Hepatocellular Carcinoma through regulating Runx2 expression

Cited by 20 publications

References 35 publications

Dysfunction of miR‐802 in tumors

Dysfunction of miR‐802 in tumors

Regulatory Role of microRNAs Targeting the Transcription Co-Factor ZNF521 in Normal Tissues and Cancers

Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review

Contact Info

Product

Resources

About